Glucagon-Like Peptide-1 (Glp-1) Analogs Market Application 2020 – Global Market Size, Industry Growth, Share Investment, Chatbots Service, Opportunities Along with The Strategic Assessment To 2026

SEATTLE, March 17, 2021, (PHARMIWEB) — Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic medications. Moreover, GLP-1 analogs provide weight reduction benefit.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/1252

High prevalence of diabetes in the U.S. and Asia Pacific are expected to drive growth of the Glucagon-like peptide-1 analogs market

According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients suffered from diabetes worldwide. According to World Health Organization (WHO) report 2017, diabetes is one of top three cause of death among the non-communicable diseases. According to the same source China (114.4 million), India (72.9 million) and the U.S. (30.2 million) are top three economies with high prevalence of diabetes. Such high prevalence is expected to drive growth of the GLP-1 analogs market. This is also from the fact that around 212.4 million people worldwide are with undiagnosed diabetes. According to the International Diabetes Federation (IDF), the U.S. has highest prevalence of diabetes (13% of population), which is expected to drive the growth of glucagon-like peptide-1 analogs market, owing to cost effectiveness and high penetration of these product in market. GLP-1 analogs not only act in type-2 diabetes but also in type 1 diabetes with almost nil hypoglycemic effect, according to the study published in the Journal of American Health and Drug Benefit. According to study published in journal Obesity Review (2017), GLP-1 analogs aid in weight reduction of diabetic as well as non-diabetic obese patient. GLP-1 analog liraglutide is already approved in treating obese and overweight patient, which is expected to fuel the growth of the GLP-1 analogs market.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://bit.ly/3cEuTFI

Increasing awareness amongst physicians about benefits of GLP-1 analogs over conventional anti-diabetic medication is expected to propel growth of the market.

GLP-1 analogs are administered through subcutaneous injection with the help of injectable pen, which are relatively expensive (US$ 492 for 30-day therapy) as compared to conventional type-2 diabetes medication such as insulin sensitizers and secretagogues (US$ 5-9 for 30-day therapy), which is the major factor that is expected to restrain growth of the market. Moreover, there is an issue of patient compliance. For instance, GLP-1 analogs need to be administered through injection as compared to other anti-diabetic medications, which are taken orally in tablet form.

Glucagon-Like Peptide-1 Analogs Market Taxonomy:

On the basis of drug:

• Exenatide
• Liraglutide
• Lixisenatide
• Dulaglutide
• Semaglutide
• Albiglutide

On the basis of distribution channel:

• Retail Pharmacy
• Hospital pharmacy

Exenatide is the first GLP-1 analog approved in 2005, marketed by AstraZeneca under brand names Byetta and Byedureon Bcise. Its patent expired in October 2017. Teva got approval to commercialize the generic version of Byetta and its abbreviated new drug application is under FDA review. Novo Nordisk in October 2017, received the FDA approval for once-a-week GLP-1 analog semaglutide. GSK announced to discontinue the global sale of albiglutide brand Tanzeum, Eperzan from July 2018 due to low profits. Taspoglutide is a molecule being developed by Roche targeting once a week dosing as against daily dosing regimen of other GLP-1 analogs. However, in 2016 it decided to halt clinical development due to high gastrointestinal side effects and hypersensitivity reactions.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/glucagon-like-peptide-1-analogs-market-1252

Key players operating in the global Glucagon-like peptide-1 analogs market include Novo Nordisk, Eli-Lilly and Company, Sanofi, AstraZeneca plc, GlaxoSmithKline plc F., and Hoffmann-La Roche Ltd.

Table of Content

Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market Research Report
Section 1: Global Glucagon-Like Peptide-1 (Glp-1) Analogs Industry Overview
Section 2: Global Economic Impact on Glucagon-Like Peptide-1 (Glp-1) Analogs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Glucagon-Like Peptide-1 (Glp-1) Analogs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Glucagon-Like Peptide-1 (Glp-1) Analogs Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837